Vyleesi and Levothyroxine Interaction: What You Need to Know

Why This Combination Raises Questions

Bremelanotide (brand name Vyleesi) and levothyroxine are prescribed for completely unrelated conditions, but the overlap in patient demographics makes co-prescribing common. Vyleesi is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Hypothyroidism affects roughly 5% of the U.S. population aged 12 and older, with women disproportionately represented [2]. A premenopausal woman taking levothyroxine for Hashimoto's thyroiditis or post-thyroidectomy replacement who also receives a Vyleesi prescription has reason to ask whether the two drugs interact.

The FDA label for bremelanotide does not list levothyroxine as a contraindicated or cautioned co-medication [1]. The levothyroxine label, by contrast, carries a broad warning about drugs and substances that alter gastrointestinal motility or gastric pH, because levothyroxine depends on an intact and predictable absorption window in the proximal small intestine [3]. That absorption window is where the clinical concern sits. Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system, and one downstream effect is reduced gastric motility, which manifests clinically as the high rate of nausea reported in the RECONNECT trials [4].

Pharmacokinetic Profile of Each Drug

Bremelanotide is administered as a 1.75 mg subcutaneous injection, reaching peak plasma concentration (Tmax) in approximately 1 hour [1]. It is not meaningfully metabolized by cytochrome P450 enzymes. The drug undergoes hydrolysis into inactive metabolites, and renal clearance accounts for about 65% of elimination. Its half-life is roughly 2.7 hours. Because bremelanotide bypasses the GI tract entirely through subcutaneous delivery, it does not compete with oral drugs for intestinal absorption.

Levothyroxine, on the other hand, is almost entirely dependent on GI absorption. Bioavailability ranges from 40% to 80% depending on fasting state, gastric pH, and intestinal transit time [3]. The American Thyroid Association (ATA) recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast, to maximize absorption [5]. Peak absorption occurs in the jejunum and upper ileum. Anything that slows gastric emptying can delay delivery of the drug to that absorptive segment, reduce total bioavailability, or both.

The practical concern is timing. Bremelanotide's effect on GI motility begins within minutes of injection and can persist for several hours. If levothyroxine is sitting in the stomach during that window, its absorption profile shifts in unpredictable ways [3].

Mechanism of the Interaction: Gastric Motility, Not CYP Enzymes

This is not a classic cytochrome P450 interaction. Bremelanotide has no clinically significant effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic concentrations [1]. It is also not a substrate or inhibitor of P-glycoprotein in a clinically meaningful way. The FDA-mandated drug interaction studies for bremelanotide focused on naltrexone (an opioid antagonist commonly co-prescribed for HSDD-adjacent indications) and oral indomethacin, and found a slowed rate of absorption for oral drugs taken near bremelanotide dosing [1].

In the indomethacin interaction study referenced in the Vyleesi prescribing information, co-administration with bremelanotide reduced indomethacin Cmax by approximately 25% and delayed Tmax by about 1 hour [1]. Indomethacin has a relatively wide therapeutic index, so this effect was not considered clinically meaningful for that drug. Levothyroxine does not share that margin.

The ATA guidelines note that "even small changes in levothyroxine absorption can produce clinically significant shifts in serum TSH," particularly in patients who are athyreotic (post-thyroidectomy or post-radioactive iodine ablation) [5]. A 20% to 25% reduction in levothyroxine absorption, analogous to what was observed with indomethacin, could push TSH outside the target range.

Severity Assessment: Low to Moderate, but Monitor

No drug-drug interaction (DDI) databases classify the bremelanotide-levothyroxine combination as contraindicated or severe. The interaction is best classified as moderate based on pharmacological reasoning and the narrow therapeutic index of levothyroxine. The Endocrine Society's 2014 clinical practice guideline on hypothyroidism management states: "Medications that impair levothyroxine absorption should be taken at least 4 hours apart from levothyroxine" [6]. That guidance covers calcium, iron, proton pump inhibitors, and by extension, any drug that meaningfully slows gastric transit.

The FDA label for Vyleesi recommends that patients "avoid use of another oral drug within 1 hour of bremelanotide injection" if the drug has a narrow therapeutic index or requires rapid onset [1]. Levothyroxine fits the first criterion. Applying both guidelines together produces a clear clinical recommendation: separate the doses.

Dr. Kenneth Burman, then chief of the Endocrine Section at MedStar Washington Hospital Center, wrote in a 2009 review of levothyroxine pharmacology: "The list of medications and supplements that interfere with levothyroxine absorption continues to grow, and clinicians should routinely ask about new medications at every thyroid follow-up visit" [7]. That statement, published in Thyroid, remains the standard of practice.

Dose-Timing Strategy

The simplest approach works. Levothyroxine should be taken in the morning on an empty stomach, following ATA recommendations of 30 to 60 minutes before food [5]. Bremelanotide is an as-needed medication used before anticipated sexual activity, with a maximum of one injection per 24 hours and no more than 8 doses per month [1].

For most patients, levothyroxine is taken in the early morning and bremelanotide is injected in the evening. That creates a natural separation of 10 or more hours. The scenario requiring attention is a patient who takes levothyroxine at bedtime (an alternative dosing strategy supported by some data) and then uses bremelanotide within a few hours. In that case, the patient should shift levothyroxine dosing to at least 4 hours before the anticipated bremelanotide injection.

A practical timing protocol:

• Morning levothyroxine user: No change needed in most cases. Take levothyroxine at 6 to 7 AM; use Vyleesi in the evening as desired.
• Bedtime levothyroxine user: If planning to use Vyleesi, take levothyroxine at least 4 hours before injection, or switch to morning dosing on days Vyleesi will be used.
• All patients: Do not take levothyroxine within 4 hours after a bremelanotide injection, as residual effects on gastric motility may persist.

Nausea and Its Impact on Thyroid Hormone Levels

Nausea is the most common adverse event with bremelanotide. In the two phase 3 RECONNECT trials (combined N = 1,247), nausea occurred in 40.0% of bremelanotide-treated patients versus 1.3% on placebo [4]. Vomiting occurred in 4.7% of bremelanotide users. Most nausea episodes were mild to moderate and self-limited, but 7.5% of bremelanotide patients discontinued due to nausea [4].

For a patient on levothyroxine, recurrent nausea and vomiting introduce a second absorption variable beyond gastric motility. If a patient vomits within 1 to 2 hours of taking levothyroxine, the dose may be partially or completely lost. This is an uncommon scenario if the drugs are properly separated in time, but it becomes relevant if a patient deviates from the recommended timing protocol.

Persistent subclinical or overt hypothyroidism caused by reduced levothyroxine absorption can itself worsen sexual dysfunction, creating a counterproductive loop. Hypothyroidism is an independent risk factor for reduced libido and sexual satisfaction in women [8]. A 2018 study published in The Journal of Clinical Endocrinology & Metabolism (N = 3,075 women) found that women with TSH above 4.0 mIU/L had a 1.4-fold higher odds of reporting low sexual desire compared with euthyroid controls [8].

Blood Pressure Considerations

Bremelanotide causes a transient increase in blood pressure averaging 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 3 hours after injection [1]. Levothyroxine does not directly raise blood pressure, but over-replacement (suppressed TSH) can increase heart rate and systolic blood pressure through excess thyroid hormone's effects on the cardiovascular system [3].

The additive cardiovascular burden is minimal in most premenopausal women. It becomes more relevant in patients with pre-existing hypertension, a group in which the Vyleesi label advises blood pressure monitoring before each dose [1]. The FDA specifically notes that bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].

If a patient's levothyroxine dose is inadvertently too high (from over-correction or dose adjustment) and bremelanotide is layered on top, the combined cardiovascular stimulation warrants attention. This is another reason to keep TSH monitoring current.

Monitoring Protocol After Starting Vyleesi

For any patient already stable on levothyroxine who begins bremelanotide:

1. Baseline TSH and free T4 should be documented before or within one week of starting Vyleesi if labs are not recent (within 3 months).
2. Recheck TSH at 6 to 8 weeks after the first bremelanotide dose, consistent with standard practice for any new medication that may alter levothyroxine absorption [5].
3. If TSH rises above the patient's target range, increase levothyroxine dose by 12.5 to 25 mcg and recheck in 6 weeks.
4. If the patient discontinues bremelanotide, recheck TSH in 6 to 8 weeks and reduce the levothyroxine dose if needed to avoid iatrogenic thyrotoxicosis.
5. Document Vyleesi use frequency. A patient using bremelanotide once per month has far less exposure than one using 8 doses per month. Dose frequency affects the clinical significance of any absorption interaction.

The ATA recommends TSH rechecking whenever "a medication known to affect thyroid hormone absorption or metabolism is started, stopped, or changed in dose" [5]. Bremelanotide fits that description based on its GI motility effects.

Other Bremelanotide Drug Interactions Worth Knowing

Beyond levothyroxine, clinicians and patients should be aware of a few other interactions documented in the Vyleesi label [1]:

• Naltrexone: Co-administration decreased bremelanotide exposure by approximately 40% in a small study. The mechanism is not fully characterized, but concurrent use is not recommended [1].
• Oral medications with narrow therapeutic indices: The FDA label broadly cautions that bremelanotide may delay absorption of co-administered oral drugs. This applies to warfarin, phenytoin, cyclosporine, and similar agents.
• Alcohol: No formal interaction study was performed, but both bremelanotide and alcohol can lower blood pressure in certain contexts (bremelanotide transiently raises it, then it may dip below baseline). Combined use may increase flushing and nausea.

Bremelanotide does not interact with hormonal contraceptives based on available data [1]. This is relevant because many HSDD patients of reproductive age use oral or transdermal contraceptives concurrently.

When to Involve Your Prescriber

Patients should contact their prescriber if they experience new or worsening fatigue, cold intolerance, constipation, weight gain, or cognitive sluggishness after starting Vyleesi. These symptoms may indicate rising TSH from reduced levothyroxine absorption. They should also report recurrent vomiting within hours of taking levothyroxine on days they use bremelanotide.

A single skipped or poorly absorbed levothyroxine dose is clinically insignificant given the drug's long half-life of approximately 7 days [3]. Repeated absorption disruption over weeks, however, can gradually raise TSH and produce symptomatic hypothyroidism.